Fampridine Gets Committee Nod With Caveat: Must Study Lower Doses
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Peripheral and Central Nervous System Drugs Advisory Committee recommended further studies of lower doses of Acorda's MS drug fampridine to reduce risk of seizure.